Humanity has a profound demographic problem and it’s not overpopulation. On the contrary, men are becoming more infertile and the quality of their sperm is deteriorating, leading to health problems.
Read More
Our Hidden Gems series has provided insight into companies and industries with direct access to company CEOs. As a follow-up, we thought we would look back at our participating companies to determine the best-performing stocks post our webinars.
Read More
Memphasys Ltd CEO and Executive Chairman Alison Coutts presents at the ShareCafe Hidden Gems Webinar on June 26, 2020. Memphasys is an Australian publicly-listed bio-separations company developing and commercialising innovative separation techniques based on the Company’s proprietary membrane technology.
Read More
ASX-listed Memphasys (MEM), has developed a novel device to separate and select sperm more quickly and effectively than the current methods. Dubbed Felix, the device uses electrical fields and membranes to sort the sperm by quality and size.
Read MoreMemphasys’ Executive Chair, Alison Coutts, was interviewed at the Finance News Network Investor Event on November 29 2019. The interview and presentation can be viewed by clicking the above link.
Read MoreProfessor John Aitken, PhD, ScD, FRSE, Head of the Medical Faculty at Newcastle University, Australia, and a global leader in Assisted Reproductive Technology (ART) research is interviewed about the Felix Device and its potential application in the area of male infertility and the future needs globally of the IVF and ART industries.
Read More
The flagging housing market and sagging consumer sentiment ahead of the federal and NSW elections have affected the performance of an unlikely ASX-listed exponent – the assisted reproduction outfit Virtus Health (VRT, $3.98).
Read More
